ZENFLEX Pro™ drug-eluting stent for femoropopliteal artery blockages

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, single-arm post-market registry enrolling up to 153 adults with symptomatic femoropopliteal artery stenosis or occlusion. Participants will receive the ZENFLEX Pro peripheral drug-eluting stent and be followed with clinical visits and imaging at 1, 6, and 12 months. The primary endpoint is primary patency at 12 months, with safety and device performance monitored throughout follow-up. Lesion eligibility includes native superficial femoral and proximal popliteal segments with vessel diameters 4.0–6.5 mm and lesion lengths within the 10–140 mm range (CTOs ≤120 mm where applicable).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Aged 18 to 80 years, regardless of gender. (2) Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3, 4 or 5. (3) Subject (or legal guardian, if applicable) is willing and able to provide consent before to the performance of any study specific tests or procedures, has signed the consent form and agrees to attend all required follow-up visits.

Angiographic Inclusion Criteria:

Eligible subjects must meet all of the following angiographic criteria:

1. Stenotic, restenotic or occlusive lesion(s) located in the native superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) (i.e., within the P1 segment):

   1. Degree of stenosis ≥70% by visual angiographic assessment.
   2. Vessel diameter ≥4.0 mm and ≤6.5 mm.
   3. Total lesion length (or series of lesions) ≥ 10 mm and ≤ 140 mm (Note: Lesion segment(s) must be fully covered with one stent).
   4. Chronic total occlusion with a total lesion length of ≤120 mm.
2. Patent popliteal and infrapopliteal arteries, with single-vessel runoff or better, defined as at least one of the three vessels remaining patent (i.e., \<50% stenosis) down to the ankle or foot.

Exclusion Criteria:

* Clinical exclusion criteria:

Subjects will be excluded from the study if any of the following conditions are present:

1. Pregnant or breastfeeding women, or women/men planning to conceive.
2. Subjects who have had or are planned for major amputation (at or above the ankle level).
3. Subjects known to be allergic or intolerant to materials used in the investigational device or treatment drugs, including nitinol, paclitaxel, aspirin, clopidogrel, heparin, rivaroxaban, contrast agents, etc.
4. Subjects with serum creatinine ≥2.5 mg/dL or currently undergoing dialysis.
5. Subjects with known, uncorrectable hemorrhagic disorders or severe coagulation dysfunction (prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≥2 times the upper limit of normal, or platelet count \<80×10⁹/L).
6. Previously stented target lesion/vessel.
7. Target lesion/vessel previously treated with drug-coated balloon \<12 months prior to enrollment.
8. Subjects with a life expectancy of less than 1 year.
9. Subjects who have received local or systemic thrombolysis treatment within 48 hours prior to enrollment.
10. Subjects diagnosed with major clinical diseases or unstable conditions within the past 3 months, such as severe heart failure, unstable angina, myocardial infarction, transient ischemic attack or stroke, severe neurological or psychiatric history, severe infections, gastrointestinal bleeding, or active disseminated intravascular coagulation.
11. Subjects currently participating in another clinical trial involving drugs or medical devices.
12. Subjects whom the investigator considers unsuitable for participation in the clinical trial.

Angiographic exclusion criteria:

1. Presence of aneurysm in the target vessel.
2. Heavily calcified lesions (Peripheral Arterial Calcium Scoring System \[PACSS\] grades 3-4).
3. The target lesion requires the use of plaque excision, laser, or other debulking devices that may damage the vessel intima.
4. The guidewire cannot pass through the target lesion, or percutaneous transluminal angioplasty (PTA) balloon cannot be used for pre-dilation.
5. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment.

Where it's running

• Cardiovascular
  Chrzanów, Chrzanow, Poland Recruiting

Study contacts

• Study coordinator: Qiqing BO, Clinical Operations Manager
• Email: qq.bo@zyloxmedical.com
• Phone: +86 18610591755

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing

  A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jang XI · NCT07881588

• Predictors of Major Adverse Limb Events After Iliac Artery Stenting

  This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.

  Recruiting I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Milan, Mi · NCT07672249

• New prodrug CG-0255 Besylate vs Plavix in healthy adults

  This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.

  Recruiting Phase 1 Shanghai CureGene Pharmaceutical Co., Ltd. · Miami, Florida · NCT07619885

• Radial and Ulnar Access in Vascular Interventions Registry

  This registry tests how often radial or ulnar artery access is used and what happens afterward in routine vascular procedures.

  Recruiting Mersin Medicalpark Hastanesi · Mersin, Mezitli · NCT07614386

• Remote versus in-person 30-second sit-to-stand testing for people with peripheral artery disease

  This project will test whether doing the 30-second sit-to-stand test by video works as well as doing it in person for adults aged 18–65 with Fontaine stage I–II peripheral artery disease who have a smartphone.

  Recruiting Izmir Democracy University · Izmir, Balçova · NCT07497360

• Imaging plaque activity across the body in people with symptomatic peripheral arterial disease

  This project will use whole-body PET-CT and CT angiography with several tracers to see if imaging can detect inflammation, microcalcification, and clot activity in people with symptomatic peripheral arterial disease.

  Recruiting University of Edinburgh · Edinburgh, Midlothian · NCT07472049

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.